CPE China

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world class team of investment professionals and supported by over 200 domestic and international investors, CPE knows China like no one else and is a globally minded long-term value investor. The firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage. CPE follows a disciplined investment approach to preserve and grow its investors’ capital. The firm’s private equity portfolio of more than 100 companies is highly diversified by sector and stage of investment. CPE takes pride in its forward-looking investment philosophy and works hard to create value over the long-term for its investors and a better world.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
Ms. Jing Wu
Principal 
Functionality

CPPHARM China

CP pharmaceutical group is a leading healthcare player in China. Stock listed in H. K. since 2000.
Partnering Objectives
Headquartner in China
Qunrui Li
Deputy General Manager 

CR Sanjiu China

A leading Chinese listed company looking for cooperation opportunities in TAs such as oncology, orthopedics, CVS, respiratory, anti infection, orphan drugs, digestive and pediatric.
Website:
www.999.com.cn
Partnering Objectives
Headquartner in China
Vincent Liao
Senior Investment&BD manager 

CR999 China

one of the biggest pharmaceutics in china.
Website:
fly.999.com.cn
Partnering Objectives
Headquartner in China
秋霞 黄
投资项目经理 

Creacion Ventures China

Creacion Ventures is an USD fund of 150million, set up in 2020, focusing on investing cross border biotech companies. We spin off from 6 Dimensions.
Website:
NM
Partnering Objectives
Headquartner in China
Kathy Kang
associate 

Crinetics Pharmaceuticals United States

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Business Development
Headquartner in China
Biotech/Pharma Category
Mr. Greg Solis
Business Strategy Associate 
Functionality

Crossject USA Inc United States

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.

Year of foundation
2001
Headquartner in China
Assets Information 1
Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis. We also have a Medtech model where we can inject 0.2-0.7ml of your drug (small or large molecule) IM or SQ.
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1
needle free auto-injector
Medtech Development Stage
Don Zinn
VP US Business 
Functionality

Crosswave Management United States

Seed and startup-scale investor focused on healthcare. Also provides cross-border partnering services.
Dr. Charles Hsu
Managing Partner 
Functionality

CRUise Lebanon

CRUise is the largest SMO Network in MEA region, we are aiming to have a network of clinical research units and Key Opinion Leaders interested in Clinical Research. CRUise will ensure the quality of research by having a network with unified international standards.

Company Size (Fulltime employees)
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Sharing CRUise concept with the attendees and having partners
Headquartner in China
Hadil Noureddine
Project Manager 
Functionality

CStone China

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
Partnering Objectives
Headquartner in China
Ping Zhao
Greater China General Manager and Head of Commercial Operations